{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:46:55Z","timestamp":1780444015499,"version":"3.54.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The well-being of people who use drugs (PWUD) continues to be threatened by substances of unknown type or quantity in the unregulated street drug supply. Current efforts to monitor the drug supply are limited in population reach and comparability. This restricts capacity to identify and develop measures that safeguard the health of PWUD. This study describes the development of a low-barrier system for monitoring the contents of drugs in the unregulated street supply. Early results for pilot sites are presented and compared across regions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The drug content monitoring system integrates a low-barrier survey and broad spectrum urine toxicology screening to compare substances expected to be consumed and those actually in the drug supply. The system prototype was developed by harm reduction pilot projects in British Columbia (BC) and Montreal with participation of PWUD. Data were collected from harm reduction supply distribution site clients in BC, Edmonton and Montreal between May 2018\u2013March 2019. Survey and urine toxicology data were linked via anonymous codes and analyzed descriptively by region for trends in self-reported and detected use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The sample consisted of 878 participants from 40 sites across 3 regions. Reported use of substances, their detection, and concordance between the two varied across regions. Methamphetamine use was reported and detected most frequently in BC (reported: 62.8%; detected: 72.2%) and Edmonton (58.3%; 68.8%). In Montreal, high concordance was also observed between reported (74.5%) and detected (86.5%) cocaine\/crack use. Among those with fentanyl detected, the percentage of participants who used fentanyl unintentionally ranged from 36.1% in BC, 78.6% in Edmonton and 90.9% in Montreal.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study is the first to describe a feasible, scalable monitoring system for the unregulated drug supply that can contrast expected and actual drug use and compare trends across regions. The system used principles of flexibility, capacity-building and community participation in its design. Results are well-suited to meet the needs of PWUD and inform the local harm reduction services they rely on. Further standardization of the survey tool and knowledge mobilization is needed to expand the system to new jurisdictions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-021-11757-x","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T12:03:00Z","timestamp":1631707380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Towards cross-Canada monitoring of the unregulated street drug supply"],"prefix":"10.1186","volume":"21","author":[{"given":"Emily","family":"Biggar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Papamihali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Hyshka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marliss","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Payer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Maloney-Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A.","family":"Buxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"11757_CR1","unstructured":"Special advisory committee on the epidemic of opioid overdoses. Opioid- and stimulant-related harms in Canada (December 2020): Public Health Agency of Canada; 2020. https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants. Accessed 24 Feb 2021"},{"key":"11757_CR2","unstructured":"Payer DE, Young M, Maloney-Hall B, Leclerc P, Buxton JA, Canadian Community Epidemiology Network on Drug Use, et al. Adulterants, Contaminants and Co-occurring Substances in Drugs on the Illegal Market in Canada An Analysis of Data from Drug Seizures, Drug Checking and Urine Toxicology. Can Centre Subst Use Addict. 2020; https:\/\/www.ccsa.ca\/sites\/default\/files\/2020-04\/CCSA-CCENDU-Adulterants-Contaminants-Co-occurring-Substances-in-Drugs-Canada-Report-2020-en.pdf. Accessed 24 Feb 2021."},{"issue":"1","key":"11757_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1477-7517-6-30","volume":"6","author":"L Knowles","year":"2009","unstructured":"Knowles L, Buxton JA, Skuridina N, Achebe I, LeGatt D, Fan S, et al. Levamisole tainted cocaine causing severe neutropenia in Alberta and British Columbia. Harm Reduct J. 2009;6(1):30. https:\/\/doi.org\/10.1186\/1477-7517-6-30.","journal-title":"Harm Reduct J"},{"issue":"1","key":"11757_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0033354919887741","volume":"135","author":"VM Singh","year":"2020","unstructured":"Singh VM, Browne T, Montgomery J. The emerging role of toxic adulterants in street drugs in the US illicit opioid crisis. Public Health Rep. 2020;135(1):6\u201310. https:\/\/doi.org\/10.1177\/0033354919887741.","journal-title":"Public Health Rep"},{"issue":"8","key":"11757_CR5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/10826084.2016.1271432","volume":"52","author":"A Al-Tayyib","year":"2017","unstructured":"Al-Tayyib A, Koester S, Langegger S, Raville L. Heroin and methamphetamine injection: an emerging drug use pattern. Subst Use Misuse. 2017;52(8):1051\u20138. https:\/\/doi.org\/10.1080\/10826084.2016.1271432.","journal-title":"Subst Use Misuse"},{"issue":"2","key":"11757_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2105\/AJPH.2019.305412","volume":"110","author":"TJ Cicero","year":"2019","unstructured":"Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2019;110(2):244\u201350. https:\/\/doi.org\/10.2105\/AJPH.2019.305412.","journal-title":"Am J Public Health"},{"issue":"Pt A","key":"11757_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuropharm.2017.10.016","volume":"134","author":"P Armenian","year":"2018","unstructured":"Armenian P, Vo KT, Barr-Walker J, Lynch KL. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology. 2018;134(Pt A):121\u201332. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.10.016.","journal-title":"Neuropharmacology"},{"issue":"9810","key":"11757_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(11)61138-0","volume":"379","author":"L Degenhardt","year":"2012","unstructured":"Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(11)61138-0.","journal-title":"Lancet"},{"issue":"6","key":"11757_CR9","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1465-3362.2009.00077.x","volume":"28","author":"J Zhao","year":"2009","unstructured":"Zhao J, Stockwell T, Macdonald S. Non\u2013response bias in alcohol and drug population surveys. Drug Alcohol Rev. 2009;28(6):648\u201357. https:\/\/doi.org\/10.1111\/j.1465-3362.2009.00077.x.","journal-title":"Drug Alcohol Rev"},{"key":"11757_CR10","volume-title":"Chapter 3: HIV\/AIDS Epi updates, July 2010 \u2013 HIV testing and surveillance systems in Canada. Government of Canada","author":"Public Health Agency of Canada","year":"2011","unstructured":"Public Health Agency of Canada. Chapter 3: HIV\/AIDS Epi updates, July 2010 \u2013 HIV testing and surveillance systems in Canada. Government of Canada. 2011. https:\/\/www.canada.ca\/en\/public-health\/services\/hiv-aids\/publications\/epi-updates\/chapter-3-hiv-testing-surveillance-systems-canada.html. Accessed 24 Feb 2021."},{"key":"11757_CR11","volume-title":"Summary of key findings from Y-Track Phase 6 (2009\u20132012). Centre for communicable diseases and infection control, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada","author":"Public Health Agency of Canada","year":"2016","unstructured":"Public Health Agency of Canada. Summary of key findings from Y-Track Phase 6 (2009\u20132012). Centre for communicable diseases and infection control, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada 2016. https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/diseases-conditions\/y-track-2002-2009\/y-track-2009-2012-eng.pdf. Accessed 24 Feb 2021."},{"issue":"9","key":"11757_CR12","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/aje\/kwq479","volume":"173","author":"J Bruneau","year":"2011","unstructured":"Bruneau J, Daniel M, Abrahamowicz M, Zang G, Lamothe F, Vincelette J. Trends in human immunodeficiency virus incidence and risk behavior among injection drug users in Montreal, Canada: a 16-year longitudinal study. Am J Epidemiol. 2011;173(9):1049\u201358. https:\/\/doi.org\/10.1093\/aje\/kwq479.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"11757_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.puhe.2007.02.016","volume":"122","author":"N Fairbairn","year":"2008","unstructured":"Fairbairn N, Wood E, Stoltz J, Li K, Montaner J, Kerr T. Crystal methamphetamine use associated with non-fatal overdose among a cohort of injection drug users in Vancouver. Public Health. 2008;122(1):70\u20138. https:\/\/doi.org\/10.1016\/j.puhe.2007.02.016.","journal-title":"Public Health"},{"key":"11757_CR14","doi-asserted-by":"publisher","first-page":"107579","DOI":"10.1016\/j.drugalcdep.2019.107579","volume":"205","author":"J Goldman-Hasbun","year":"2019","unstructured":"Goldman-Hasbun J, Kerr T, Nosova E, Shulha H, Wood E, DeBeck K. Initiation into heroin use among street-involved youth in a Canadian setting: a longitudinal cohort study. Drug Alcohol Depend. 2019;205:107579. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107579.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"11757_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/00126334-200208150-00007","volume":"30","author":"C Hankins","year":"2002","unstructured":"Hankins C, Alary M, Parent R, Blanchette C, Claessens C. SurvUDI working group. Continuing HIV transmission among injection drug users in eastern Central Canada: the SurvUDI study, 1995 to 2000. J Acquir Immune Defic Syndr. 2002;30(5):514\u201321. https:\/\/doi.org\/10.1097\/00126334-200208150-00007.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"11757_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/dar.12427","volume":"36","author":"E Hyshka","year":"2017","unstructured":"Hyshka E, Anderson JT, Wild TC. Perceived unmet need and barriers to care amongst street-involved people who use illicit drugs. Drug Alcohol Rev. 2017;36(3):295\u2013304. https:\/\/doi.org\/10.1111\/dar.12427.","journal-title":"Drug Alcohol Rev"},{"issue":"1-2","key":"11757_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.drugalcdep.2012.05.018","volume":"126","author":"\u00c9 Roy","year":"2012","unstructured":"Roy \u00c9, Arruda N, Leclerc P, Haley N, Bruneau J, Boivin J-F. Injection of drug residue as a potential risk factor for HCV acquisition among Montreal young injection drug users. Drug Alcohol Depend. 2012;126(1-2):246\u201350. https:\/\/doi.org\/10.1016\/j.drugalcdep.2012.05.018.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"11757_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.drugalcdep.2013.05.013","volume":"133","author":"\u00c9 Roy","year":"2013","unstructured":"Roy \u00c9, Leclerc P, Morissette C, Arruda N, Blanchette C, Blouin K, et al. Prevalence and temporal trends of crack injection among injection drug users in eastern Central Canada. Drug Alcohol Depend. 2013;133(1):275\u20138. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.05.013.","journal-title":"Drug Alcohol Depend"},{"key":"11757_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drugpo.2017.05.012","volume":"45","author":"\u00c9 Roy","year":"2017","unstructured":"Roy \u00c9, Arruda N, Leclerc P, Morissette C, Blanchette C, Blouin K, et al. Drug use practices among people who inject drugs in a context of drug market changes: challenges for optimal coverage of harm reduction programs. Int J Drug Policy. 2017;45:18\u201324. https:\/\/doi.org\/10.1016\/j.drugpo.2017.05.012.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"11757_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1747-597X-6-34","volume":"6","author":"L Ti","year":"2011","unstructured":"Ti L, Buxton J, Wood E, Zhang R, Montaner J, Kerr T. Difficulty accessing crack pipes and crack pipe sharing among people who use drugs in Vancouver, Canada. Substance abuse treatment, prevention, and. Policy. 2011;6(1):34. https:\/\/doi.org\/10.1186\/1747-597X-6-34.","journal-title":"Policy"},{"issue":"1","key":"11757_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7517-3-18","volume":"3","author":"E Wood","year":"2006","unstructured":"Wood E, Stoltz J-A, Montaner JS, Kerr T. Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J. 2006;3(1):18. https:\/\/doi.org\/10.1186\/1477-7517-3-18.","journal-title":"Harm Reduct J"},{"key":"11757_CR22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.drugalcdep.2017.12.032","volume":"185","author":"N Baldwin","year":"2018","unstructured":"Baldwin N, Gray R, Goel A, Wood E, Buxton JA, Rieb LM. Fentanyl and heroin contained in seized illicit drugs and overdose-related deaths in British Columbia, Canada: an observational analysis. Drug Alcohol Depend. 2018;185:322\u20137. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.12.032.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"11757_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.35502\/jcswb.92","volume":"4","author":"JA Buxton","year":"2019","unstructured":"Buxton JA, Spearn B, Amlani A, Kuo M, Lysyshyn M, Young S, et al. The British Columbia Drug Overdose and Alert Partnership: Interpreting and sharing timely illicit drug information to reduce harms. JCSWB. 2019;4(1):4\u20139. https:\/\/doi.org\/10.35502\/jcswb.92.","journal-title":"JCSWB"},{"issue":"23","key":"11757_CR24","doi-asserted-by":"publisher","first-page":"724","DOI":"10.15585\/mmwr.mm6923a3","volume":"69","author":"Z Dezman","year":"2020","unstructured":"Dezman Z, Schwartz B, Billing A, Massey E, Artigiani EE, Factor J, et al. Notes from the field: high prevalence of fentanyl detected by the Maryland emergency department drug surveillance system \u2014 Baltimore, Maryland, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(23):724\u20136. https:\/\/doi.org\/10.15585\/mmwr.mm6923a3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"11757_CR25","volume-title":"Illicit drug overdose deaths in BC: Findings of coroners\u2019 investigations. Ministry of Public Safety and Solicitor General","author":"Ministry of Public Safety and Solicitor General","year":"2018","unstructured":"Ministry of Public Safety and Solicitor General. Illicit drug overdose deaths in BC: Findings of coroners\u2019 investigations. Ministry of Public Safety and Solicitor General. 2018. https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/statistical\/illicitdrugoverdosedeathsinbc-findingsofcoronersinvestigations-final.pdf Accessed 24 Feb 2021."},{"key":"11757_CR26","doi-asserted-by":"publisher","first-page":"102661","DOI":"10.1016\/j.drugpo.2020.102661","volume":"77","author":"TC Green","year":"2020","unstructured":"Green TC, Park JN, Gilbert M, McKenzie M, Struth E, Lucas R, et al. An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. Int J Drug Policy. 2020;77:102661. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102661.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"11757_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12954-018-0252-8","volume":"15","author":"M Karamouzian","year":"2018","unstructured":"Karamouzian M, Dohoo C, Forsting S, McNeil R, Kerr T, Lysyshyn M. Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada. Harm Reduct J. 2018;15(1):46. https:\/\/doi.org\/10.1186\/s12954-018-0252-8.","journal-title":"Harm Reduct J"},{"key":"11757_CR28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugpo.2018.08.007","volume":"63","author":"NC Peiper","year":"2019","unstructured":"Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the southeastern United States. Int J Drug Policy. 2019;63:122\u20138. https:\/\/doi.org\/10.1016\/j.drugpo.2018.08.007.","journal-title":"Int J Drug Policy"},{"key":"11757_CR29","volume-title":"Drug checking as a harm reduction intervention: evidence review report. British Columbia Centre on Substance Use","author":"T Kerr","year":"2017","unstructured":"Kerr T, Tupper K. Drug checking as a harm reduction intervention: evidence review report. British Columbia Centre on Substance Use 2017. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2017\/12\/Drug-Checking-Evidence-Review-Report.pdf. Accessed 24 Feb 2021."},{"issue":"1","key":"11757_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1477-7517-4-10","volume":"4","author":"SJ Fielden","year":"2007","unstructured":"Fielden SJ, Marsh DC. It\u2019s time for Canadian community early warning systems for illicit drug overdoses. Harm Reduct J. 2007;4(1):10. https:\/\/doi.org\/10.1186\/1477-7517-4-10.","journal-title":"Harm Reduct J"},{"issue":"1","key":"11757_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12954-015-0088-4","volume":"12","author":"A Amlani","year":"2015","unstructured":"Amlani A, McKee G, Khamis N, Raghukumar G, Tsang E, Buxton JA. Why the FUSS (fentanyl urine screen study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada. Harm Reduct J. 2015;12(1):54. https:\/\/doi.org\/10.1186\/s12954-015-0088-4.","journal-title":"Harm Reduct J"},{"issue":"1","key":"11757_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7517-11-13","volume":"11","author":"M Kuo","year":"2014","unstructured":"Kuo M, Shamsian A, Tzemis D, Buxton JA. A drug use survey among clients of harm reduction sites across British Columbia, Canada, 2012. Harm Reduct J. 2014;11(1):13. https:\/\/doi.org\/10.1186\/1477-7517-11-13.","journal-title":"Harm Reduct J"},{"key":"11757_CR33","unstructured":"Leclerc P, Graham B, Papmihali K, Hyshka E, Taylor M, Tremblay C, Carron N, Morissette C, Buxton J. Towards a cross-Canada surveillance of illicit drug content [PowerPoint presentation]. Issues of Substance Conference. Ottawa; 2019."},{"issue":"1","key":"11757_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4065\/83.1.66","volume":"83","author":"KE Moeller","year":"2008","unstructured":"Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83(1):66\u201376. https:\/\/doi.org\/10.4065\/83.1.66.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"11757_CR35","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/dar.12558","volume":"37","author":"CJ Cherpitel","year":"2018","unstructured":"Cherpitel CJ, Ye Y, Stockwell T, Vallance K, Chow C. Recall bias across 7 days in self-reported alcohol consumption prior to injury among emergency department patients. Drug Alcohol Rev. 2018;37(3):382\u20138. https:\/\/doi.org\/10.1111\/dar.12558.","journal-title":"Drug Alcohol Rev"},{"key":"11757_CR36","doi-asserted-by":"publisher","first-page":"102665","DOI":"10.1016\/j.drugpo.2020.102665","volume":"77","author":"M Karamouzian","year":"2020","unstructured":"Karamouzian M, Papamihali K, Graham B, Crabtree A, Mill C, Kuo M, et al. Known fentanyl use among clients of harm reduction sites in British Columbia, Canada. Int J Drug Policy. 2020;77:102665. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102665.","journal-title":"Int J Drug Policy"},{"key":"11757_CR37","volume-title":"BC harm reduction client survey. British Columbia Centre for Disease Control","author":"British Columbia Centre for Disease Control","year":"2018","unstructured":"British Columbia Centre for Disease Control. BC harm reduction client survey. British Columbia Centre for Disease Control. 2018 http:\/\/www.bccdc.ca\/resource-gallery\/Documents\/Statistics%20and%20Research\/Statistics%20and%20Reports\/Overdose\/BC_HR_survey_2018_May2.pdf. Accessed Feb 24 2021."},{"issue":"1","key":"11757_CR38","first-page":"40","volume":"29","author":"F Leri","year":"2004","unstructured":"Leri F, Stewart J, Tremblay A, Bruneau J. Heroin and cocaine co-use in a group of injection drug users in Montreal. J Psychiatry Neurosci. 2004;29(1):40\u20137.","journal-title":"J Psychiatry Neurosci"},{"issue":"2","key":"11757_CR39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.drugpo.2012.10.004","volume":"24","author":"\u00c9 Roy","year":"2013","unstructured":"Roy \u00c9, Richer I, Arruda N, Vandermeerschen J, Bruneau J. Patterns of cocaine and opioid co-use and polyroutes of administration among street-based cocaine users in Montreal, Canada. Int J Drug Policy. 2013;24(2):142\u20139. https:\/\/doi.org\/10.1016\/j.drugpo.2012.10.004.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"11757_CR40","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1177\/003335491613100315","volume":"131","author":"GRT Walton","year":"2016","unstructured":"Walton GRT, Hayashi K, Bach P, Dong H, Kerr T, Ahamad K, et al. The impact of benzodiazepine use on mortality among polysubstance users in Vancouver, Canada. Public Health Rep. 2016;131(3):491\u20139. https:\/\/doi.org\/10.1177\/003335491613100315.","journal-title":"Public Health Rep"},{"issue":"4","key":"11757_CR41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/YCO.0000000000000069","volume":"27","author":"JP Connor","year":"2014","unstructured":"Connor JP, Gullo MJ, White A, Kelly AB. Polysubstance use: diagnostic challenges, patterns of use and health. Curr Opin Psychiatry. 2014;27(4):269\u201375. https:\/\/doi.org\/10.1097\/YCO.0000000000000069.","journal-title":"Curr Opin Psychiatry"},{"key":"11757_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.drugalcdep.2019.03.026","volume":"201","author":"KE Schneider","year":"2019","unstructured":"Schneider KE, Park JN, Allen ST, Weir BW, Sherman SG. Patterns of polysubstance use and overdose among people who inject drugs in Baltimore, Maryland: a latent class analysis. Drug Alcohol Depend. 2019;201:71\u20137. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.03.026.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"11757_CR43","doi-asserted-by":"publisher","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","volume":"69","author":"N Wilson","year":"2020","unstructured":"Wilson N, Kariisa M, Seth P, Smith HIV, Davis N. Drug and opioid-involved overdose deaths \u2014 United States, 2017\u20132018. MMWR Morb Mortal Wkly Rep. 2020;69(11):290\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm6911a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"11757_CR44","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1007\/s00204-017-1947-4","volume":"91","author":"TM Brunt","year":"2017","unstructured":"Brunt TM, van den Berg J, Pennings E, Venhuis B. Adverse effects of levamisole in cocaine users: a review and risk assessment. Arch Toxicol. 2017;91(6):2303\u201313. https:\/\/doi.org\/10.1007\/s00204-017-1947-4.","journal-title":"Arch Toxicol"},{"issue":"2","key":"11757_CR45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/FTD.0000000000000851","volume":"43","author":"KM Midthun","year":"2021","unstructured":"Midthun KM, Nelson LS, Logan BK. Levamisole\u2014a toxic adulterant in illicit drug preparations: a review. Ther Drug Monit. 2021;43(2):221\u20138. https:\/\/doi.org\/10.1097\/FTD.0000000000000851.","journal-title":"Ther Drug Monit"},{"key":"11757_CR46","doi-asserted-by":"publisher","first-page":"108418","DOI":"10.1016\/j.jsat.2021.108418","volume":"130","author":"G Bardwell","year":"2021","unstructured":"Bardwell G, Ivsins A, Soc\u00edas ME, Kerr T. Examining factors that shape use and access to diverted prescription opioids during an overdose crisis: a qualitative study in Vancouver, Canada. J Subst Abuse Treat. 2021;130:108418. https:\/\/doi.org\/10.1016\/j.jsat.2021.108418.","journal-title":"J Subst Abuse Treat"},{"key":"11757_CR47","volume-title":"Novel Synthetic Opioids in Counterfeit Pharmaceuticals and Other Illicit Street Drugs. Canadian Centre on Substance Use and Addiction","author":"Canadian Community Epidemiology Network on Drug Use","year":"2016","unstructured":"Canadian Community Epidemiology Network on Drug Use. Novel Synthetic Opioids in Counterfeit Pharmaceuticals and Other Illicit Street Drugs. Canadian Centre on Substance Use and Addiction. 2016. https:\/\/www.ccsa.ca\/sites\/default\/files\/2019-04\/CCSA-CCENDU-Novel-Synthetic-Opioids-Bulletin-2016-en.pdf. Accessed 20 May 2021."},{"key":"11757_CR48","doi-asserted-by":"publisher","first-page":"k3207","DOI":"10.1136\/bmj.k3207","volume":"362","author":"T Gomes","year":"2018","unstructured":"Gomes T, Khuu W, Martins D, Tadrous M, Mamdani MM, Paterson JM, et al. Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ. 2018;362:k3207. https:\/\/doi.org\/10.1136\/bmj.k3207.","journal-title":"BMJ"},{"issue":"1","key":"11757_CR49","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12954-020-00436-6","volume":"17","author":"K Papamihali","year":"2020","unstructured":"Papamihali K, Yoon M, Graham B, Karamouzian M, Slaunwhite AK, Tsang V, et al. Convenience and comfort: reasons reported for using drugs alone among clients of harm reduction sites in British Columbia, Canada. Harm Reduct J. 2020;17(1):90. https:\/\/doi.org\/10.1186\/s12954-020-00436-6.","journal-title":"Harm Reduct J"},{"key":"11757_CR50","doi-asserted-by":"publisher","first-page":"107609","DOI":"10.1016\/j.drugalcdep.2019.107609","volume":"205","author":"A Moustaqim-Barrette","year":"2019","unstructured":"Moustaqim-Barrette A, Papamihali K, Crabtree A, Graham B, Karamouzian M, Buxton JA. Correlates of take-home naloxone kit possession among people who use drugs in British Columbia: a cross-sectional analysis. Drug Alcohol Depend. 2019;205:107609. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107609.","journal-title":"Drug Alcohol Depend"},{"key":"11757_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08897077.2019.1680479","volume":"28","author":"VWL Tsang","year":"2019","unstructured":"Tsang VWL, Papamihali K, Crabtree A, Buxton JA. Acceptability of technological solutions for overdose monitoring: perspectives of people who use drugs. Subst Abus. 2019;28:1\u201310. https:\/\/doi.org\/10.1080\/08897077.2019.1680479.","journal-title":"Subst Abus"},{"issue":"1","key":"11757_CR52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13011-016-0048-3","volume":"11","author":"AM Greer","year":"2016","unstructured":"Greer AM, Hu S, Amlani A, Moreheart S, Sampson O, Buxton JA. Patient perspectives of methadone formulation change in British Columbia, Canada: outcomes of a provincial survey. Subst Abuse Treat Prev Policy. 2016;11(1):3. https:\/\/doi.org\/10.1186\/s13011-016-0048-3.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"11757_CR53","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.drugpo.2019.01.017","volume":"66","author":"B Wallace","year":"2019","unstructured":"Wallace B, Pagan F, Pauly BB. The implementation of overdose prevention sites as a novel and nimble response during an illegal drug overdose public health emergency. Int J Drug Policy. 2019;66:64\u201372. https:\/\/doi.org\/10.1016\/j.drugpo.2019.01.017.","journal-title":"Int J Drug Policy"},{"key":"11757_CR54","volume-title":"Perceptions of adulteration and quality assurance practices reported by people who use drugs. British Columbia Centre for Disease Control","author":"RN Kling","year":"2015","unstructured":"Kling RN, Baljak Y, Amlani A, Buxton JA. Perceptions of adulteration and quality assurance practices reported by people who use drugs. British Columbia Centre for Disease Control 2015. http:\/\/www.bccdc.ca\/resource-gallery\/Documents\/Educational%20Materials\/Epid\/Other\/CDAFinalReport.pdf. Accessed Feb 24 2021."},{"issue":"1","key":"11757_CR55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1089\/env.2012.0017","volume":"6","author":"CL Balazs","year":"2013","unstructured":"Balazs CL, Morello-Frosch R. The three Rs: how community-based participatory research strengthens the rigor, relevance, and reach of science. Environ Justice. 2013;6(1):9\u201316. https:\/\/doi.org\/10.1089\/env.2012.0017.","journal-title":"Environ Justice"},{"key":"11757_CR56","volume-title":"Illicit drug toxicity deaths in BC January 1, 2010 \u2013 December 31, 2020","author":"BC Coroners Service","year":"2021","unstructured":"BC Coroners Service. Illicit drug toxicity deaths in BC January 1, 2010 \u2013 December 31, 2020. 2021. Ministry of Public Safety and Solicitor General. https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/statistical\/illicit-drug.pdf. Accessed 24 Feb 2021."},{"key":"11757_CR57","volume-title":"Statement from the Chief Public Health Officer of Canada on COVID-19. Government of Canada","author":"Public Health Agency of Canada","year":"2020","unstructured":"Public Health Agency of Canada. Statement from the Chief Public Health Officer of Canada on COVID-19. Government of Canada. 2020. https:\/\/www.canada.ca\/en\/public-health\/news\/2020\/05\/statement-from-the-chief-public-health-officer-of-canada-on-covid-198.html. Accessed 24 Feb 2021."},{"issue":"5","key":"11757_CR58","doi-asserted-by":"publisher","first-page":"e0252090","DOI":"10.1371\/journal.pone.0252090","volume":"16","author":"K Papamihali","year":"2021","unstructured":"Papamihali K, Collins D, Karamouzian M, Purssell R, Graham B, Buxton J. A. Crystal methamphetamine use in British Columbia, Canada: A cross-sectional study of people who access harm reduction services. PLoS One. 2021;16(5):e0252090.","journal-title":"PLoS One"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-11757-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-021-11757-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-11757-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T12:05:19Z","timestamp":1631707519000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-021-11757-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["11757"],"URL":"https:\/\/doi.org\/10.1186\/s12889-021-11757-x","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,15]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study-related ethics approval was obtained through the University of British Columbia Office of Behavioural Research Ethics (Approval Number: H07\u201300570) for BC and Edmonton, and through the Comit\u00e9 d\u2019\u00e9thique de la recherche \u2013 D\u00e9pendances, In\u00e9galit\u00e9s sociales et Sant\u00e9 publique for Montreal. Informed consent was obtained from all participants for the study. All protocols were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1678"}}